17102-63-5

Usage

Uses

Used in Azaquinone-Methide-Mediated Depolymerization:
4-BROMO-2-METHOXYBENZYL ALCOHOL 97 is used as a reagent in the azaquinone-methide-mediated depolymerization of aromatic carbamate oligomers. This process is crucial for the synthesis of various organic compounds and materials.
Used in Pharmaceutical Industry:
4-BROMO-2-METHOXYBENZYL ALCOHOL 97 is used as an intermediate in the synthesis of pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs.
Used in Chemical Synthesis:
4-BROMO-2-METHOXYBENZYL ALCOHOL 97 is used as a starting material in the synthesis of various organic compounds, including dyes, pigments, and other specialty chemicals.
Used in Research and Development:
4-BROMO-2-METHOXYBENZYL ALCOHOL 97 is used as a research compound in academic and industrial laboratories. Its unique properties make it a valuable tool for studying various chemical reactions and processes.

InChI:InChI=1/C8H9BrO2/c1-11-8-4-7(9)3-2-6(8)5-10/h2-4,10H,5H2,1H3

Upstream product

• 43192-33-2 4-bromo-2-methoxybenzaldehyde 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 

Downstream Products

• 890038-13-8 4-(hydroxymethyl)-3-methoxybenzonitrile 
• 1446945-66-9 C₁₆H₁₂BrNO₄ 
• 1446946-10-6 C₁₈H₂₆BrN₃O₄ 
• 1388049-28-2 O-(4-bromo-2-methoxybenzyl)hydroxylamine 
• 1446946-23-1 7-[3-amino-4-(4'-bromo-2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446945-84-1 C₁₉H₂₄BrN₃O₄ 
• 1446945-97-6 C₁₉H₂₆BrN₃O₅ 
• 1404094-91-2 (2‐methoxy‐4‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)phenyl)methanol 
• 1425051-81-5 C₃₇H₃₉BN₄O₁₁ 
• 1425052-02-3 C₂₉H₄₄BNO₇Si 
• 1425051-88-2 C₂₃H₃₀BNO₇ 
• 1425051-90-6 C₃₀H₃₄BN₃O₁₀ 
• 1425052-03-4 C₃₈H₅₃BN₂O₁₀Si 
• 1425052-04-5 C₃₂H₃₉BN₂O₁₀ 

Relevant academic research and scientific papers

Small molecule inhibitors of anthrax lethal factor toxin

This manuscript describes the preparation of new small molecule inhibitors of Bacillus anthracis lethal factor. Our starting point was the symmetrical, bis-quinolinyl compound 1 (NSC 12155). Optimization of one half of this molecule led to new LF inhibitors that were desymmetrized to afford more drug-like compounds.

Synthesis, in vitro antimycobacterial and antibacterial evaluation of IMB-070593 derivatives containing a substituted benzyloxime moiety

A series of novel IMB-070593 derivatives containing a substituted benzyloxime moiety and displaying a remarkable improvement in lipophilicity were synthesized and evaluated for their in vitro antimycobacterial and antibacterial activity. Our results reveal that the target compounds 19a-m have considerable Gram-positive activity (MIC: 0.008-32 μg/mL), although they are generally less active than the reference drugs against the Gram-negative strains. In particular, compounds 19h, 19j, 19k and 19m show good activity (MICs: 0.008-4 μg/mL) against all of the tested Gram-positive strains, including ciprofloxacin (CPFX)- and/or levofloxacin (LVFX)-resistant MSSA, MRSA and MSSE. Moreover, compound 19l (MIC: 0.125 μg/mL) is found to be 2-4 fold more active than the parent IMB070593, CPFX and LVFX against M. tuberculosis H37Rv ATCC 27294.

PHENOL COMPOUNDS ALS TOLL -LIKE RECEPTOR 7 AGONISTS

The invention concerns compounds of Formula (I): wherein R1, R2, R3 and Q are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK2 receptor antagonists

Herein we describe the synthesis of a series of new potent tachykinin NK2 receptor antagonists by the modulation of the Cand N-terminal moieties of ibodutant (MEN 15596, 1). The Nterminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK2 receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK2 receptor. Selected compounds were tested in vivo confirming their activity as NK2 antagonists. In particular, after both iv and id administration to guinea pig, compound 61b was able to antagonize NK2-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I): Chemical formula should be inserted here as it appears on the abstract in paper form. or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Binding of Phenylalkylamine Derivatives at 5-HT1C and 5-HT2 Serotonin Receptors: Evidence for a Lack of Selectivity

Certain phenyalkylamine derivatives have been considered to bind selectively at 5-HT2 serotonin receptors.It is now recognized that the most widely used derivatives, i.e., 1-(2,5-dimethoxy-4-X-phenyl)-2-aminopropanes where X = Me (DOM), Br (DOB), and I (DOI) (1-3, respectively) also bind at the more recently identified population of serotonin 5-HT1C receptors.The purpose of the present investigation was to determine whether simple phenylalkylamines bind selectively at one population of receptors over the other.An examination of 34 derivatives reveals (i) similar structure-affinity relationships and (ii) a significant correlation (r = >0.9, n = 25) between 5-HT1C and 5-HT2 affinity.None of the compounds included in the present study displayed more than a 10-fold selectivity for one population of these receptors over the other; the results suggest that these compounds (including the widely used 5-HT2 agonists DOB and DOI) are 5-HT1C/5-HT2 agents.